Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M29,868Revenue (TTM) $M2,019Net Margin (%)8.8Altman Z-Score11.5
Enterprise Value $M29,146EPS (TTM) $0.7Operating Margin %14.6Piotroski F-Score8
P/E(ttm)171Beneish M-Score-2.7Pre-tax Margin (%)10.7Higher ROA y-yY
Price/Book19.910-y EBITDA Growth Rate %--Quick Ratio3.7Cash flow > EarningsY
Price/Sales14.65-y EBITDA Growth Rate %--Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow64.3y-y EBITDA Growth Rate %--ROA % (ttm)6.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)15.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M249ROIC % (ttm)36.7Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VRTX is held by these investors:



VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ALTSHULER DAVIDEVP, Global Research and CSO 2017-05-15Sell181$114.374.85view
SMITH IAN FEVP, CFO & COO 2017-05-15Sell294$114.924.35view
Sachdev AmitEVP, CRO 2017-05-15Sell116$114.374.85view
Silva Paul MSVP & Corp Controller 2017-05-15Sell271$114.644.61view
Chodakewitz JeffreyEVP GMDA, CMO 2017-05-02Sell8,979$121.05-0.93view
LEIDEN JEFFREY MCEO & President 2017-04-28Sell157,200$119.50.35view
ALTSHULER DAVIDEVP, Global Research and CSO 2017-04-28Sell7,500$120-0.07view
Arbuckle Stuart AEVP\Chief Commercial Officer 2017-04-28Sell28,320$119.50.35view
Chodakewitz JeffreyEVP GMDA, CMO 2017-04-05Sell8,021$1145.19view
Chodakewitz JeffreyEVP GMDA, CMO 2017-04-03Sell2,291$108.8510.17view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 
    Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
    Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
    Piotroski F-Score in the Real World Dec 19 2016 
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
    Edward Owens Top 2nd Quarter Investments Aug 03 2016 
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 

    More From Other Websites
    Vertex CEO: Our goal is to have one medicine for all cyst... May 23 2017
    Vertex Undergoes FTC Scrubbing for Deal on CF Treatment May 22 2017
    Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will? May 19 2017
    Vertex launches college scholarship program for cystic fibrosis patients, families May 19 2017
    Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their... May 19 2017
    Vertex to Present at the UBS Healthcare Conference on May 23 May 18 2017
    Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion May 18 2017
    Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation... May 18 2017
    Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks... May 18 2017
    Vertex boosts Kalydeco sales forecast after FDA approves for more patients May 18 2017
    Vertex shares up more than 1% after FDA drug approval May 17 2017
    FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis... May 17 2017
    Love High-Growth? Here Are 3 Stocks to Consider May 17 2017
    5 Toxic Stocks to Steer Clear Of or Play Short Right Now May 17 2017
    Why Is Vertex Pharma (VRTX) Stock Soaring This Year? May 16 2017
    Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 May 14 2017
    3 Best Stocks in Personalized Medicine May 14 2017
    CWALT, Inc. Mortgage Pass-Through Certificates, Series 2006-45T1 -- Moody's Affirms Seven Classes of... May 11 2017
    I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards May 09 2017
    Here's Why Vertex Pharmaceuticals Incorporated Gained 8% in April May 08 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)